Antithrombotic treatment is a key component of secondary prevention following acute
coronary syndromes (ACS). Although dual antiplatelet therapy is standard therapy post …

In the past two decades there has been a succession of advances in the development of
anticoagulant and antiplatelet therapies to be used in the treatment of ACS. Despite optimal …

Background Patients with previous acute coronary syndrome (ACS) are at high risk of
recurrent adverse cardiovascular events. Recently, prolonged dual antiplatelet therapy …

Common to the pathogenesis of acute coronary syndromes (ACS) is the formation of arterial
thrombus, which results from platelet activation and triggering of the coagulation cascade. 1 …

Risk-based antithrombotic strategies after percutaneous coronary intervention (PCI). Dual
antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor inhibitor is indicated for …

Background Nine oral antithrombotic medications currently available in the United States
and Europe have been studied in clinical trials for secondary prevention of cardiac events …

An acute coronary syndrome (ACS) event is associated with a high risk of recurrent ACS,
stroke, and death. To ameliorate the risk of subsequent events, current guidelines for ST …

Objectives: The authors assessed the use of dual antiplatelet therapy (DAPT) and outcomes
in patients undergoing percutaneous coronary intervention (PCI) during the ROCKET AF …

Antiplatelet therapy, the cornerstone of post coronary stenting antithrombotic therapy,
reduces the rate of hard clinical endpoints in patients treated both conservatively and …

Background Dual antiplatelet therapy (DAPT), aspirin plus a P2Y12 inhibitor, is the standard
antithrombotic treatment following acute coronary syndromes. The factor Xa inhibitor …